Altre lingue MEI Pharma, Inc. Deutsche Boerse AG

Azioni

MMI0

US55279B3015

Tempo differito Deutsche Boerse AG Altri mercati azionari 08:13:00 18/04/2023			Variaz. 5gg	Var. 1 gen.
4,2 ^EUR	-17,32%		-.--%	-.--%

09/05	MEI Pharma, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 31 marzo 2024	CI
11/04	MEI Pharma, Inc. annuncia un piano strategico per sfruttare i recenti dati clinici positivi di Voruciclib e ME-344	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/05
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	09/05
MEI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	09/05
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	12/04
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	11/04
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	11/04
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	11/04
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	10/04
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	26/03
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	15/02
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	13/02
MEI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	13/02
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	16/01
MEI Pharma : Change in Certifying Accountants - Form 8-K	26/12
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	14/12
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	11/12
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023	11/12
Earnings Flash (MEIP) MEI PHARMA Posts Q1 Revenue $65.3M	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue MEI Pharma, Inc. Deutsche Boerse AG

Azioni

MMI0

US55279B3015

Altre lingue

Filtri